Clinical Trial Update: Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the PET imaging tracer [18F] FEPPA as a marker of inflammation in subjects with Alzheimer's disease, Parkinson's disease, and multiple …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Multiple Sclerosis
• Parkinson Disease

Drugs mentioned

• [18F] FEPPA (FEPPA)

Snippet

Sponsor: Institute for Neurodegenerative Disorders | Conditions: Alzheimer Disease, Parkinson Disease | Phase 1 | Status: COMPLETED